

Maxime Samson

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5528847/maxime-samson-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

2,476
citations

26
h-index

47
g-index

154
ext. papers

3,439
ext. citations

5.4
avg, IF

4.71
L-index

#	Paper	IF	Citations
110	Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD.. <i>Frontiers in Immunology</i> , 2022 , 13, 827712	8.4	0
109	New Insights into the Pathogenesis of Giant Cell Arteritis: Mechanisms Involved in Maintaining Vascular Inflammation. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2905	5.1	1
108	Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Rheumatology</i> , 2021 , 60, 4355-4360	3.9	5
107	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis.. <i>Presse Medicale</i> , 2021 , 51, 104107	2.2	0
106	Heamatological malignancies in giant cell arteritis: a French population-based study. <i>Rheumatology</i> , 2021 , 60, 5408-5412	3.9	2
105	Myeloproliferative neoplasms and clonal hematopoiesis in patients with giant cell arteritis: a case-control and exploratory study. <i>Rheumatology</i> , 2021 ,	3.9	3
104	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 436-441	5.3	3
103	Giant cell arteritis-related aortic dissection: A multicenter retrospective study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 430-435	5.3	3
102	Specific Follicular Helper T Cell Signature in Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1233-1243	9.5	10
101	Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis. <i>Arthritis Research and Therapy</i> , 2021 , 23, 143	5.7	4
100	Myocardial infarction during giant cell arteritis: A cohort study. <i>European Journal of Internal Medicine</i> , 2021 , 89, 30-38	3.9	2
99	Mucosal-associated invariant T cells in Giant Cell Arteritis. <i>Journal of Autoimmunity</i> , 2021 , 121, 102652	15.5	1
98	Ustekinumab For the Treatment of Giant Cell Arteritis: Comment on the Article by Matza et al. <i>Arthritis Care and Research</i> , 2021 , 73, 1058-1059	4.7	3
97	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 498-503	9.5	18
96	Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody-Associated Vasculitides: A Case-Control Study. <i>Arthritis and Rheumatology</i> , 2021 , 73, 286-294	9.5	9
95	Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis. <i>Clinical and Translational Immunology</i> , 2021 , 10, e1332	6.8	6
94	Efficiency of human monocyte-derived suppressor cell-based treatment in graft-versus-host disease prevention while preserving graft-versus-leukemia effect. <i>OncImmunity</i> , 2021 , 10, 1880046	7.2	1

93	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. <i>Arthritis and Rheumatology</i> , 2021 , 74, 295	9.5	5
92	Acute myocarditis with autoimmune features: one-year follow-up with CMR. <i>Heart and Vessels</i> , 2021 , 1	2.1	
91	Epidemiology of major relapse in giant cell arteritis: A study-level meta-analysis. <i>Autoimmunity Reviews</i> , 2021 , 21, 102930	13.6	5
90	« Fausses et autres » artérites temporales. <i>Revue Du Rhumatisme Monographies</i> , 2021 , 88, 317-323	0	
89	Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis. <i>Rheumatology</i> , 2020 , 59, 2970-2975	3.9	3
88	ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance. <i>Presse Medicale</i> , 2020 , 49, 104031	2.2	6
87	Discussion suite à la communication: « Artérite à cellules géantes: de la physiopathologie aux nouvelles cibles thérapeutiques ». <i>Bulletin De L'Académie Nationale De Médecine</i> , 2020 , 204, 53-57	0.1	
86	Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1759-1763	4.5	11
85	OP0148 MEPOLIZUMAB FOR EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): A RETROSPECTIVE REAL-WORLD EUROPEAN STUDY ON 142 PATIENTS. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 94-95	2.4	1
84	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). <i>Orphanet Journal of Rare Diseases</i> , 2020 , 15, 351	4.2	13
83	Glucocorticoids impair HDL-mediated cholesterol efflux besides increased HDL cholesterol concentration: a proof of concept. <i>European Journal of Endocrinology</i> , 2020 , 183, 297-306	6.5	1
82	Artérite à cellules géantes : de la physiopathologie aux nouvelles cibles thérapeutiques. <i>Bulletin De L'Académie Nationale De Médecine</i> , 2020 , 204, 18-28	0.1	
81	Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review. <i>Autoimmunity Reviews</i> , 2020 , 19, 102446	13.6	11
80	Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. <i>Rheumatology</i> , 2020 , 59, 2250-2257	3.9	7
79	Risk of malignancy in patients treated for systemic necrotising vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 431-433	2.4	2
78	Antiplatelet Antibodies Do Not Predict the Response to Intravenous Immunoglobulins during Immune Thrombocytopenia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
77	Impact du confinement dû au COVID-19 sur la prise en charge et le contrôle de l'artérite à cellules géantes. <i>Revue De Médecine Interne</i> , 2020 , 41, A17-A18	0.1	
76	Restauration de la réponse T régulatrice après traitement par tocilizumab au cours de l'artérite à cellules géantes. <i>Revue De Médecine Interne</i> , 2020 , 41, A61-A62	0.1	

75	Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 179-187	8	44
74	Full-field optical coherence tomography for the diagnosis of giant cell arteritis. <i>PLoS ONE</i> , 2020 , 15, e0234165	1	165
73	Analysis of IL-6 measurement in patients with GCA treated with tocilizumab should consider concomitant treatment with prednisone. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e102	2.4	6
72	Prevalence of Giant Cell Arteritis Relapse in Patients Treated With Glucocorticoids: A Meta-Analysis. <i>Arthritis Care and Research</i> , 2020 , 72, 838-849	4.7	28
71	Endovascular stenting for chronic femoro-iliac venous obstructive disease: Clinical efficacy and short-term outcomes. <i>Diagnostic and Interventional Imaging</i> , 2020 , 101, 15-23	5.4	8
70	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. <i>Journal of Autoimmunity</i> , 2020 , 106, 102338	15.5	15
69	Impact of the COVID-19 lockdown on the management and control of patients with GCA. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4
68	Distal ischemia as the initial presentation of hypereosinophilic syndrome-related arterial involvement: A case study and literature review. <i>Autoimmunity Reviews</i> , 2019 , 18, 828-830	13.6	8
67	Large-vessel vasculitis diagnosed between 50 and 60 years: Case-control study based on 183 cases and 183 controls aged over 60 years. <i>Autoimmunity Reviews</i> , 2019 , 18, 714-720	13.6	7
66	Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients. <i>Rheumatology</i> , 2019 , 58, 1565-1573	3.9	15
65	Automatic Generation of Test Oracles from Component Based Software Architectures. <i>Lecture Notes in Computer Science</i> , 2019 , 261-269	0.9	1
64	Arteritis de células gigantes (enfermedad de Horton) - Seudopoliartritis rizomflica. <i>EMC - Tratado De Medicina</i> , 2019 , 23, 1-10	0	0
63	Réduction du nombre de perfusions de rituximab au début du traitement d'entretien des vascularites associées aux ANCA. Résultats d'une analyse post-hoc de l'essai contrôlé randomisé MAINRITSAN2. <i>Revue De Medecine Interne</i> , 2019 , 40, A61	0.1	
62	Giant cell arteritis-related aortitis with positive or negative temporal artery biopsy: a French multicentre study. <i>Scandinavian Journal of Rheumatology</i> , 2019 , 48, 474-481	1.9	2
61	Concomitant association of giant cell arteritis and malignancy: a multicenter retrospective case-control study. <i>Clinical Rheumatology</i> , 2019 , 38, 1243-1249	3.9	6
60	mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G. <i>Rheumatology</i> , 2018 , 57, 1011-1020	3.9	22
59	Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. <i>Autoimmunity Reviews</i> , 2018 , 17, 391-398	13.6	50
58	Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1143-1149	2.4	123

57	CT analysis of the aorta in giant-cell arteritis: a case-control study. <i>European Radiology</i> , 2018 , 28, 3676-3684	15
56	Ustekinumab inhibits Th1 and Th17 polarisation in a patient with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, e6	2.4 20
55	Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2018 , 93, 139-144	15.5 3
54	Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study. <i>European Journal of Internal Medicine</i> , 2018 , 57, 96-104	3.9 20
53	Fully Leafed Tree-Like Polyominoes and Polycubes. <i>Lecture Notes in Computer Science</i> , 2018 , 206-218	0.9 1
52	Biological treatments in giant cell arteritis & Takayasu arteritis. <i>European Journal of Internal Medicine</i> , 2018 , 50, 12-19	3.9 22
51	Venous thromboembolic events during warm autoimmune hemolytic anemia. <i>PLoS ONE</i> , 2018 , 13, e0207218	3.7 29
50	Giant Cell Arteritis-related Stroke: A Retrospective Multicenter Case-control Study. <i>Journal of Rheumatology</i> , 2017 , 44, 297-303	4.1 47
49	Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia. <i>Clinical and Experimental Immunology</i> , 2017 , 188, 275-282	6.2 19
48	Pathogenesis of immune thrombocytopenia. <i>Autoimmunity Reviews</i> , 2017 , 16, 620-632	13.6 148
47	Recent advances in our understanding of giant cell arteritis pathogenesis. <i>Autoimmunity Reviews</i> , 2017 , 16, 833-844	13.6 95
46	Physiopathologie des artérites à cellules géantes. <i>Revue Du Rhumatisme Monographies</i> , 2017 , 84, 215-222	0 1
45	Treatment of giant-cell arteritis, a literature review. <i>Modern Rheumatology</i> , 2017 , 27, 747-754	3.3 15
44	Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients. <i>PLoS ONE</i> , 2017 , 12, e0187296	3.7 9
43	Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. <i>PLoS ONE</i> , 2017 , 12, e0183844	3.7 106
42	Diagnosis of hyperferritinemia in routine clinical practice. <i>Presse Medicale</i> , 2017 , 46, e329-e338	2.2 20
41	B cell depleting therapy regulates splenic and circulating T follicular helper cells in immune thrombocytopenia. <i>Journal of Autoimmunity</i> , 2017 , 77, 89-95	15.5 19
40	T Cell Polarization toward T2/T2 and T17/T17 in Patients with IgG4-Related Disease. <i>Frontiers in Immunology</i> , 2017 , 8, 235	8.4 55

39	Etiologies and prognostic factors of leukocytoclastic vasculitis with skin involvement: A retrospective study in 112 patients. <i>Medicine (United States)</i> , 2016 , 95, e4238	1.8	23
38	Involvement and prognosis value of CD8(+) T cells in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016 , 72, 73-83	15.5	37
37	Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). <i>Revue De Medecine Interne</i> , 2016 , 37, 154-65	0.1	91
36	High Incidence of Venous Thromboembolism Events during Warm Autoimmune Hemolytic Anemia. <i>Blood</i> , 2016 , 128, 2448-2448	2.2	1
35	Endovascular stent placement for chronic post-thrombotic symptomatic ilio-femoral venous obstructive lesions: a single-center study of safety, efficacy and quality-of-life improvement. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016 , 6, 342-352	3.6	16
34	Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2274-82	9.5	59
33	Dissection aortique trait�e par corticoth�apie. <i>Revue De Medecine Interne</i> , 2016 , 37, A174	0.1	
32	Comparison of idiopathic (isolated) aortitis and giant cell arteritis-related aortitis. A French retrospective multicenter study of 117 patients. <i>Autoimmunity Reviews</i> , 2016 , 15, 571-6	13.6	30
31	Stroke associated with giant cell arteritis: a population-based study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015 , 86, 216-21	5.5	67
30	Plasma exchanges for the treatment of severe systemic necrotizing vasculitides in clinical daily practice: Data from the French Vasculitis Study Group. <i>Journal of Autoimmunity</i> , 2015 , 65, 49-55	15.5	24
29	T Lymphocyte Inhibition by Tumor-Infiltrating Dendritic Cells Involves Ectonucleotidase CD39 but Not Arginase-1. <i>BioMed Research International</i> , 2015 , 2015, 891236	3	5
28	Human monocyte-derived suppressor cells control graft-versus-host disease by inducing regulatory forkhead box protein 3-positive CD8+ T lymphocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2015 , 135, 1614-24.e4	11.5	13
27	Granulomatosis with polyangiitis: endoscopic management of tracheobronchial stenosis: results from a multicentre experience. <i>Rheumatology</i> , 2015 , 54, 1852-7	3.9	29
26	Splenic and Circulating Human T Follicular Helper Cell Regulation By B Cell Depleting Therapy during Immune Thrombocytopenia. <i>Blood</i> , 2015 , 126, 8-8	2.2	
25	Response to: 'Five Factor Score in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss; EGPA): to use or not to use?' by Moiseev and Novikov. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e13	2.4	2
24	Long-term follow-up of a randomized trial on 118 patients with polyarteritis nodosa or microscopic polyangiitis without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014 , 13, 197-205	13.6	61
23	Should mild hypogammaglobulinemia be managed as severe hypogammaglobulinemia? A study of 389 patients with secondary hypogammaglobulinemia. <i>European Journal of Internal Medicine</i> , 2014 , 25, 837-42	3.9	13
22	Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. <i>Autoimmunity Reviews</i> , 2014 , 13, 945-53	13.6	36

21	Is TNF- α really involved in giant cell arteritis pathogenesis?. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e1	2.4	8
20	Splenic TFH expansion participates in B-cell differentiation and antiplatelet-antibody production during immune thrombocytopenia. <i>Blood</i> , 2014 , 124, 2858-66	2.2	44
19	Does tocilizumab indeed reduce the frequency of Th17 cells? Comment on the article by Thiolat et al. <i>Arthritis and Rheumatology</i> , 2014 , 66, 2639-40	9.5	1
18	Severe cardiomyopathy revealing antineutrophil cytoplasmic antibodies-negative eosinophilic granulomatosis with polyangiitis. <i>Internal Medicine Journal</i> , 2014 , 44, 928-31	1.6	5
17	Rituximab: Recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. <i>Presse Medicale</i> , 2013 , 42, 1317-30	2.2	49
16	Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. <i>Journal of Autoimmunity</i> , 2013 , 43, 60-9	15.5	123
15	Reply: To PMID 22833233. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1134-5		1
14	Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole et al. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, e3	2.4	2
13	Perirenal fibrosis: make your diagnosis. <i>CKJ: Clinical Kidney Journal</i> , 2013 , 6, 543-4	4.5	1
12	Preferential splenic CD8(+) T-cell activation in rituximab-nonresponder patients with immune thrombocytopenia. <i>Blood</i> , 2013 , 122, 2477-86	2.2	30
11	Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, S65-73	2.2	4
10	Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3788-98		115
9	Do hip OA patients referred to orthopedic surgeons by general practitioners and rheumatologists differ?. <i>Clinical Rheumatology</i> , 2012 , 31, 1301-7	3.9	0
8	Circulating and intragraft TH17 cells are not increased at the early stage of chronic allograft nephropathy. <i>Transplantation Proceedings</i> , 2012 , 44, 2827-8	1.1	1
7	Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2499-503		247
6	Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange. <i>Internal Medicine Journal</i> , 2012 , 42, 95-8	1.6	4
5	Failure of Rituximab in Immune Thrombocytopenia Is Associated with the Activation of Splenic CD8 T Cells. <i>Blood</i> , 2012 , 120, 623-623	2.2	1
4	Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. <i>Blood</i> , 2011 , 118, 4394-400	2.2	82

3	Diagnostic strategy for patients with hypogammaglobulinemia in rheumatology. <i>Joint Bone Spine</i> , 2011 , 78, 241-5	2.9	28
2	Cytotoxic dendritic cells generated from cancer patients. <i>Journal of Immunology</i> , 2011 , 187, 2775-82	5.3	18
1	Dysferlin deficiency treated like refractory polymyositis. <i>Clinical Rheumatology</i> , 2010 , 29, 103-6	3.9	15